"Today, Maryland Oncology Hematology is the largest independent Medical Oncology and Hematology group in Maryland with 30 physicians practicing in 9 locations across central Maryland. Dedicated to providing the most advanced cancer care available anywhere in an atmosphere of caring compassion."

During the past decade, Maryland Oncology Hematology PA-Aquilino Cancer Center conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 7 clinical trials were completed, i.e. on average, 700% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 5 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maryland Oncology Hematology PA-Aquilino Cancer Center" #1 collaborator was "Cancer and Leukemia Group B" with 3 trials as a collaborator, "NRG Oncology" with 3 trials as a collaborator, "North Central Cancer Treatment Group" with 3 trials as a collaborator, "NCIC Clinical Trials Group" with 2 trials as a collaborator and "SWOG Cancer Research Network" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Maryland Oncology Hematology PA-Aquilino Cancer Center" are "Breast Adenocarcinoma" (3 trials), "Fallopian Tube Clear Cell Adenocarcinoma" (2 trials), "Fallopian Tube Endometrioid Adenocarcinoma" (2 trials), "Fallopian Tube Mucinous Adenocarcinoma" (2 trials) and "Fallopian Tube Serous Adenocarcinoma" (2 trials). Many other conditions were trialed in "Maryland Oncology Hematology PA-Aquilino Cancer Center" in a lesser frequency.

Most popular intervention types in "Maryland Oncology Hematology PA-Aquilino Cancer Center" are "Other" (9 trials), "Drug" (8 trials), "Biological" (7 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (8 trials), "Quality-of-Life Assessment" (6 trials), "Bevacizumab" (5 trials), "Paclitaxel" (5 trials) and "Carboplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Maryland Oncology Hematology PA-Aquilino Cancer Center" are 5 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Maryland Oncology Hematology PA-Aquilino Cancer Center". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Maryland Oncology Hematology PA-Aquilino Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Maryland Oncology Hematology PA-Aquilino Cancer Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".